The Market Reports

Index

1 Paroxysmal Nocturnal Hemoglobinuria Drug Market Overview
1.1 Product Overview and Scope of Paroxysmal Nocturnal Hemoglobinuria Drug
1.2 Paroxysmal Nocturnal Hemoglobinuria Drug Segment by Type
1.2.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Value Comparison by Type (2023-2029)
1.2.2 Eculizumab
1.2.3 Ravulizumab
1.2.4 Others
1.3 Paroxysmal Nocturnal Hemoglobinuria Drug Segment by Application
1.3.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Value by Application: (2023-2029)
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Size Estimates and Forecasts
1.4.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue 2018-2029
1.4.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales 2018-2029
1.4.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Paroxysmal Nocturnal Hemoglobinuria Drug Market Competition by Manufacturers
2.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Manufacturers (2018-2023)
2.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Average Price by Manufacturers (2018-2023)
2.4 Global Paroxysmal Nocturnal Hemoglobinuria Drug Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Paroxysmal Nocturnal Hemoglobinuria Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Paroxysmal Nocturnal Hemoglobinuria Drug, Product Type & Application
2.7 Paroxysmal Nocturnal Hemoglobinuria Drug Market Competitive Situation and Trends
2.7.1 Paroxysmal Nocturnal Hemoglobinuria Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Paroxysmal Nocturnal Hemoglobinuria Drug Players Market Share by Revenue
2.7.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Paroxysmal Nocturnal Hemoglobinuria Drug Retrospective Market Scenario by Region
3.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Region: 2018-2029
3.2.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Region: 2018-2023
3.2.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Region: 2024-2029
3.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Region: 2018-2029
3.3.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Region: 2018-2023
3.3.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Region: 2024-2029
3.4 North America Paroxysmal Nocturnal Hemoglobinuria Drug Market Facts & Figures by Country
3.4.1 North America Paroxysmal Nocturnal Hemoglobinuria Drug Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2018-2029)
3.4.3 North America Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Market Facts & Figures by Country
3.5.1 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2018-2029)
3.5.3 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2018-2029)
3.6.3 Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Market Facts & Figures by Country
3.7.1 Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2018-2029)
3.7.3 Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country (2018-2029)
3.8.3 Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Type (2018-2029)
4.1.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Type (2018-2023)
4.1.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Type (2024-2029)
4.1.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Type (2018-2029)
4.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Type (2018-2029)
4.2.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Type (2018-2023)
4.2.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Type (2024-2029)
4.2.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Type (2018-2029)
4.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Price by Type (2018-2029)
5 Segment by Application
5.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Application (2018-2029)
5.1.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Application (2018-2023)
5.1.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Application (2024-2029)
5.1.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Application (2018-2029)
5.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Application (2018-2029)
5.2.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Application (2018-2023)
5.2.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue by Application (2024-2029)
5.2.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Application (2018-2029)
5.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Apellis Pharmaceuticals
6.1.1 Apellis Pharmaceuticals Corporation Information
6.1.2 Apellis Pharmaceuticals Description and Business Overview
6.1.3 Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.1.5 Apellis Pharmaceuticals Recent Developments/Updates
6.2 Alexion Pharmaceuticals Inc
6.2.1 Alexion Pharmaceuticals Inc Corporation Information
6.2.2 Alexion Pharmaceuticals Inc Description and Business Overview
6.2.3 Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.2.5 Alexion Pharmaceuticals Inc Recent Developments/Updates
6.3 Akari Therapeutics Plc
6.3.1 Akari Therapeutics Plc Corporation Information
6.3.2 Akari Therapeutics Plc Description and Business Overview
6.3.3 Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.3.5 Akari Therapeutics Plc Recent Developments/Updates
6.4 CinnaGen Co
6.4.1 CinnaGen Co Corporation Information
6.4.2 CinnaGen Co Description and Business Overview
6.4.3 CinnaGen Co Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2018-2023)
6.4.4 CinnaGen Co Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.4.5 CinnaGen Co Recent Developments/Updates
6.5 Ra Pharmaceuticals Inc
6.5.1 Ra Pharmaceuticals Inc Corporation Information
6.5.2 Ra Pharmaceuticals Inc Description and Business Overview
6.5.3 Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.5.5 Ra Pharmaceuticals Inc Recent Developments/Updates
6.6 Amgen Inc
6.6.1 Amgen Inc Corporation Information
6.6.2 Amgen Inc Description and Business Overview
6.6.3 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.6.5 Amgen Inc Recent Developments/Updates
6.7 Achillion Pharmaceuticals Inc
6.6.1 Achillion Pharmaceuticals Inc Corporation Information
6.6.2 Achillion Pharmaceuticals Inc Description and Business Overview
6.6.3 Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.7.5 Achillion Pharmaceuticals Inc Recent Developments/Updates
6.8 Alnylam Pharmaceuticals Inc
6.8.1 Alnylam Pharmaceuticals Inc Corporation Information
6.8.2 Alnylam Pharmaceuticals Inc Description and Business Overview
6.8.3 Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.8.5 Alnylam Pharmaceuticals Inc Recent Developments/Updates
6.9 F. Hoffmann-La Roche Ltd
6.9.1 F. Hoffmann-La Roche Ltd Corporation Information
6.9.2 F. Hoffmann-La Roche Ltd Description and Business Overview
6.9.3 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2018-2023)
6.9.4 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.9.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
6.10 Novartis AG
6.10.1 Novartis AG Corporation Information
6.10.2 Novartis AG Description and Business Overview
6.10.3 Novartis AG Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Novartis AG Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.10.5 Novartis AG Recent Developments/Updates
6.11 Regeneron Pharmaceuticals Inc
6.11.1 Regeneron Pharmaceuticals Inc Corporation Information
6.11.2 Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Description and Business Overview
6.11.3 Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.11.5 Regeneron Pharmaceuticals Inc Recent Developments/Updates
6.12 BIOCAD
6.12.1 BIOCAD Corporation Information
6.12.2 BIOCAD Paroxysmal Nocturnal Hemoglobinuria Drug Description and Business Overview
6.12.3 BIOCAD Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2018-2023)
6.12.4 BIOCAD Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.12.5 BIOCAD Recent Developments/Updates
6.13 Samsung Bioepis
6.13.1 Samsung Bioepis Corporation Information
6.13.2 Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria Drug Description and Business Overview
6.13.3 Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.13.5 Samsung Bioepis Recent Developments/Updates
6.14 Amyndas Pharmaceuticals
6.14.1 Amyndas Pharmaceuticals Corporation Information
6.14.2 Amyndas Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Description and Business Overview
6.14.3 Amyndas Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Amyndas Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.14.5 Amyndas Pharmaceuticals Recent Developments/Updates
6.15 Teva Pharmaceutical Industries Ltd.
6.15.1 Teva Pharmaceutical Industries Ltd. Corporation Information
6.15.2 Teva Pharmaceutical Industries Ltd. Paroxysmal Nocturnal Hemoglobinuria Drug Description and Business Overview
6.15.3 Teva Pharmaceutical Industries Ltd. Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Teva Pharmaceutical Industries Ltd. Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.15.5 Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
6.16 LGM Pharma.
6.16.1 LGM Pharma. Corporation Information
6.16.2 LGM Pharma. Paroxysmal Nocturnal Hemoglobinuria Drug Description and Business Overview
6.16.3 LGM Pharma. Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2018-2023)
6.16.4 LGM Pharma. Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.16.5 LGM Pharma. Recent Developments/Updates
6.17 Lannett
6.17.1 Lannett Corporation Information
6.17.2 Lannett Paroxysmal Nocturnal Hemoglobinuria Drug Description and Business Overview
6.17.3 Lannett Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2018-2023)
6.17.4 Lannett Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.17.5 Lannett Recent Developments/Updates
6.18 NorthStar Rx LLC
6.18.1 NorthStar Rx LLC Corporation Information
6.18.2 NorthStar Rx LLC Paroxysmal Nocturnal Hemoglobinuria Drug Description and Business Overview
6.18.3 NorthStar Rx LLC Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2018-2023)
6.18.4 NorthStar Rx LLC Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.18.5 NorthStar Rx LLC Recent Developments/Updates
6.19 Abbott
6.19.1 Abbott Corporation Information
6.19.2 Abbott Paroxysmal Nocturnal Hemoglobinuria Drug Description and Business Overview
6.19.3 Abbott Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2018-2023)
6.19.4 Abbott Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.19.5 Abbott Recent Developments/Updates
6.20 Par Pharmaceutical
6.20.1 Par Pharmaceutical Corporation Information
6.20.2 Par Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria Drug Description and Business Overview
6.20.3 Par Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria Drug Sales, Revenue and Gross Margin (2018-2023)
6.20.4 Par Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria Drug Product Portfolio
6.20.5 Par Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Paroxysmal Nocturnal Hemoglobinuria Drug Industry Chain Analysis
7.2 Paroxysmal Nocturnal Hemoglobinuria Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Paroxysmal Nocturnal Hemoglobinuria Drug Production Mode & Process
7.4 Paroxysmal Nocturnal Hemoglobinuria Drug Sales and Marketing
7.4.1 Paroxysmal Nocturnal Hemoglobinuria Drug Sales Channels
7.4.2 Paroxysmal Nocturnal Hemoglobinuria Drug Distributors
7.5 Paroxysmal Nocturnal Hemoglobinuria Drug Customers
8 Paroxysmal Nocturnal Hemoglobinuria Drug Market Dynamics
8.1 Paroxysmal Nocturnal Hemoglobinuria Drug Industry Trends
8.2 Paroxysmal Nocturnal Hemoglobinuria Drug Market Drivers
8.3 Paroxysmal Nocturnal Hemoglobinuria Drug Market Challenges
8.4 Paroxysmal Nocturnal Hemoglobinuria Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer